Does the Arthritis Pill Rinvoq Regrow Hair in Alopecia?
Yes. In two large trials published in August 2026, about half of adults with at least half the scalp bare regrew hair to near-normal coverage after 24 weeks, and a meaningful minority regrew it all. That's the strongest response any oral JAK inhibitor has posted in severe alopecia areata. The catch: the hair holds only while you keep taking the pill, and Rinvoq still carries the JAK class boxed warning for infections, clots, and cancer.
The two trials, UP-AA1 and UP-AA2, landed in JAMA Dermatology on August 12, 2026. They enrolled 1,399 people ages 12 to 64 with at least half the scalp bare, and randomized them to Rinvoq 15 mg, 30 mg, or placebo once daily for 24 weeks. About 45% reached near-normal coverage on 15 mg and 55% on 30 mg. It's the first phase 3 evidence for upadacitinib in this disease, and it edges past every other oral JAK inhibitor tested.
The number that stood out
Near-normal, the trials' primary endpoint, means less than a fifth of the scalp is still bare. Close to normal at a glance, not perfect. What separates upadacitinib from the JAK inhibitors before it is the step past that. On placebo, essentially no one achieved complete regrowth. AbbVie calls upadacitinib the first JAK inhibitor to show complete regrowth versus placebo at week 24, and no earlier trial has published complete-regrowth numbers of that size at this timepoint.
How it stacks up against the other pills
Four other oral JAK inhibitors already have randomized data in severe alopecia areata: baricitinib and ritlecitinib (both FDA-approved), deuruxolitinib (approved for adults), and ivarmacitinib (approved in China). Below is each drug's headline result from its pivotal trial. Placebo response ran from under 1% to about 9% across them.
| Drug and dose | Regrew to near-normal | Trial and timepoint |
|---|---|---|
| Upadacitinib 15 mg | ~45% | UP-AA1/AA2, week 24 |
| Upadacitinib 30 mg | ~55% | UP-AA1/AA2, week 24 |
| Baricitinib 4 mg | 36 to 39% | BRAVE-AA1/AA2, week 36 |
| Deuruxolitinib 12 mg twice daily | ~38% | THRIVE-AA2, week 24 |
| Ritlecitinib 50 mg | ~23% | ALLEGRO, week 24 |
No head-to-head trials exist, so this isn't a clean race. Populations differ, and baricitinib was measured at week 36 rather than week 24, which flatters the earlier-timepoint numbers. Even so, upadacitinib leads the range.
Who's most likely to respond
Response tracks with dose, age, and pattern of hair loss. Adults on the 30 mg dose reached near-normal coverage in about 52% of cases. The higher dose beat the lower one in both age groups. Older studies across the JAK class point to the same weaker-response subgroups: long disease duration, the universalis or ophiasis patterns, and prior use of a different JAK inhibitor. Someone with recent-onset patchy disease responds differently from someone who has been totally bald for a decade.
The hair stays only while the drug does
Across every JAK inhibitor studied in alopecia areata so far, more than half of patients relapse after stopping, most within about three months. Upadacitinib hasn't reported its own withdrawal data yet, and there's no biological reason to expect it to break the pattern. The drug quiets the autoimmune attack on the hair follicle. It doesn't cure it. Restarting usually recaptures the response, but staying on the pill is the price of keeping the hair.
That means accepting the class safety profile long-term. Across more than 27,000 patient-years in other indications, mostly rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and inflammatory bowel disease, serious infections on 15 mg ran at about 3 per 100 patient-years, and cancers other than non-melanoma skin cancer at about 0.6 per 100 patient-years. Both comparable to adalimumab. The 30 mg dose, which drives the highest regrowth rates, carries a higher serious-infection signal than 15 mg. Rates rise in older patients and in those with cardiovascular risk factors. The FDA boxed warning for serious infections, cancer, clots, and major cardiovascular events still applies. It was extrapolated from an older tofacitinib trial in rheumatoid arthritis, and whether it fits younger dermatology patients on a JAK1-selective drug isn't settled.
Where this lands if you're weighing it
If you have severe alopecia areata, want to regrow hair, and carry low baseline risk for infection, cancer, and cardiovascular disease, upadacitinib now has the strongest published numbers of any oral JAK inhibitor. The EU has already approved it down to age 12. In the US the sNDA is filed and a decision is pending; until then, off-label prescribing is the only path. Either way, this is a decision that turns on individual risk, so a dermatologist experienced with JAK inhibitors should own the prescription.
Three things would sharpen the picture: head-to-head trials against baricitinib, ritlecitinib, or deuruxolitinib; long-term data on how many responders can eventually taper or stop without losing their hair; and alopecia-specific safety numbers separating the 15 mg and 30 mg doses. Until then, Rinvoq gives severe alopecia areata patients the best odds yet of meaningful regrowth, on the standing condition that the hair stays as long as the drug does.